​

Arcturus Therapeutics (ARCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARCT Stock Forecast

Arcturus Therapeutics (ARCT) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $10.58, with a high of $10.58 and a low of $10.58. This represents a -37.17% decline from the last price of $16.84.

$10 $16 $22 $28 $34 $40 High: $10.58 Avg: $10.58 Low: $10.58 Last Closed Price: $16.84

ARCT Stock Rating

Arcturus Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 0 Hold (0.00%), 1 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 0 6 Strong Sell Sell Hold Buy Strong Buy

ARCT Forecast vs Benchmarks

TypeNameUpside
StockArcturus Therapeutics-37.17%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$10.58$12.18
Last Closing Price$16.84$16.84$16.84
Upside/Downside--37.17%-27.67%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2538---11
Dec, 2437---10
Nov, 243711-12
Oct, 244711-13
Sep, 244711-13
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Whitney IjemCanaccord Genuity$10.58$3.02250.33%-37.17%
Aug 06, 2024Whitney IjemCanaccord Genuity$10.30$3.20221.88%-38.84%
Jul 02, 2024Ed ArceH.C. Wainwright$8.58$3.38153.85%-49.05%
May 31, 2024Yasmeen RahimiPiper Sandler$20.02$5.64254.96%18.88%
May 10, 2024Whitney IjemCanaccord Genuity$12.30$3.83221.15%-26.96%
Mar 19, 2024Yale JenLaidlaw$11.30$4.83133.95%-32.90%
Nov 02, 2022Gena WangBarclays$25.00$21.6915.26%48.46%
May 11, 2022Goldman Sachs$14.00$13.563.24%-16.86%
Nov 09, 2021Madhu KumarGoldman Sachs$30.00$36.23-17.20%78.15%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024Leerink PartnersBuyBuyhold
Sep 17, 2024Canaccord GenuityBuyBuyhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024Piper SandlerOverweightOverweighthold
Jul 02, 2024H.C. WainwrightBuyBuyhold
Jun 07, 2024William BlairOutperformOutperformhold
May 31, 2024Piper SandlerOverweightOverweighthold
May 29, 2024CitigroupBuyBuyhold
Mar 11, 2024Wells FargoBuyBuyhold
Jul 24, 2023William BlairOutperforminitialise

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.51$-7.86$0.35$-1.12-----
Avg Forecast$-3.02$-7.87$-5.83$-1.78$-2.43$-2.15$0.11$2.28$6.88
High Forecast$-4.49$-11.72$-11.86$-2.46$-3.03$-8.86$-0.32$-5.24$3.50
Low Forecast$-2.11$-5.51$-3.24$-0.85$-1.41$8.61$0.94$19.58$15.94
Surprise %16.23%-0.13%-106.00%-37.08%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.54M$12.36M$205.75M$157.75M-----
Avg Forecast$9.76M$23.84M$53.87M$173.81M$169.49M$205.12M$315.95M$451.96M$682.31M
High Forecast$7.50M$18.34M$35.43M$131.16M$152.63M$152.56M$309.09M$451.96M$424.08M
Low Forecast$13.43M$32.81M$96.72M$246.32M$200.06M$346.54M$322.82M$451.96M$1.37B
Surprise %-2.23%-48.17%281.91%-9.24%-----

Net Income Forecast

$-250M $-90M $70M $230M $390M $550M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.36M$-206.86M$9.35M$-29.73M-----
Avg Forecast$-80.30M$-166.49M$-191.63M$-29.73M$-62.64M$-52.90M$8.24M$77.19M$183.29M
High Forecast$-119.58M$-199.79M$-229.95M$-35.67M$-80.80M$-235.86M$-8.58M$-139.50M$93.11M
Low Forecast$-56.19M$-133.19M$-153.30M$-23.78M$-37.63M$229.25M$25.06M$521.26M$424.36M
Surprise %-11.13%24.25%-104.88%------

ARCT Forecast FAQ

Is Arcturus Therapeutics stock a buy?

Arcturus Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Arcturus Therapeutics is a favorable investment for most analysts.

What is Arcturus Therapeutics's price target?

Arcturus Therapeutics's price target, set by 7 Wall Street analysts, averages $10.58 over the next 12 months. The price target range spans from $10.58 at the low end to $10.58 at the high end, suggesting a potential -37.17% change from the previous close price of $16.84.

How does Arcturus Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Arcturus Therapeutics stock forecast shows a -37.17% downside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Arcturus Therapeutics over the past three months?

  • January 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 58.33% Buy, 8.33% Hold, 8.33% Sell, 0% Strong Sell.

What is Arcturus Therapeutics’s EPS forecast?

Arcturus Therapeutics's average annual EPS forecast for its fiscal year ending in December is -2.43 for 2024, a 116.96% increase from the reported $-1.12 in 2023. The prediction for 2025 is $-2.15, $0.11 for 2026, $2.28 for 2027, and $6.88 for 2028.

What is Arcturus Therapeutics’s revenue forecast?

Arcturus Therapeutics's average annual revenue forecast for its fiscal year ending in December is $169.49M for 2024, a 7.44% increase from the reported $157.75M in 2023. The forecast for 2025 is $205.12M, $315.95M for 2026, $451.96M for 2027, and $682.31M for 2028.

What is Arcturus Therapeutics’s net income forecast?

For its fiscal year ending in December, Arcturus Therapeutics's average annual net income forecast is $-62.643M for 2024, reflecting an 110.74% increase from the reported $-29.725M in 2023. The projection for 2025 is $-52.902M, $8.24M for 2026, $77.19M for 2027, and $183.29M for 2028.